Cellectar Biosciences, Inc. CLRB
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- -58.31%
- 1 year
- -63.28%
- Market cap
- 11.63M
- EPS (ttm)
- -3.46
- Shares out
- 41.27M
- Forward P/E
- -0.10
- YTD return
- -58.31%
- 1-year return
- -63.28%
- Volume
- 85.50K
- Avg volume
- 88.66K
- Open
- 1.28
- Previous close
- 1.31
- Day's range
- 1.23 – 1.37
- 52-week range
- 1.12 – 4.70
- Beta
- 1.01
- Analysts
- Buy
- Price target
- 5.67 (+360.7%)
2Y -59.67 (-97.98%)
Key statistics
- Enterprise value
- 59.34M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -20.48M
- Total cash
- 25.87M
- Total debt
- 530.86K
- Return on equity
- -796.67%
- Short % of float
- 5.06%
- 50-day average
- 1.60
- 200-day average
- 2.48
Analyst view
Consensus: buy
- Target (low)
- 1.00
- Target (mean)
- 5.67
- Target (high)
- 13.00
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.3525.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 18, 2024 | Sep 1, 2024 | -0.35 | -0.55 | -0.20 | -57.14% |
| May 14, 2024 | Mar 1, 2024 | -0.50 | -0.40 | +0.10 | +20.00% |
| Mar 27, 2024 | Dec 1, 2023 | -0.59 | -0.66 | -0.07 | -11.86% |
| Aug 14, 2023 | Jun 1, 2023 | -0.69 | -0.73 | -0.04 | -5.80% |
| May 4, 2023 | Mar 1, 2023 | -0.75 | -0.76 | -0.01 | -1.33% |
| Mar 9, 2023 | Dec 1, 2022 | -0.83 | -0.55 | +0.28 | +33.73% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | Oppenheimer | down | Outperform | Perform |
| Nov 19, 2024 | Oppenheimer | main | Outperform | Outperform |
| Mar 28, 2024 | Roth MKM | main | Buy | Buy |
| Mar 28, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Mar 4, 2024 | Roth MKM | reit | Buy | Buy |
| Nov 4, 2022 | HC Wainwright & Co. | main | — | Buy |
About Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cellectar.com
News
Cellectar Biosciences To Present Three Posters For Its Radiopharmaceutical Candidate At American Society Of Hematology Annual Meeting 
Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition 
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026 
Cellectar Biosciences Reports Results From Case Study Highlighting Durable Complete Response In Heavily Pretreated Patient With Diffuse Large B-Cell Lymphoma Treated With Iopofosine I 131 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Your note
Sign in to keep a note on CLRB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARUSO JAMES V | Chief Executive Officer | Stock Award(Grant) | Dec 7, 2023 | 49,236 |
| KOLEAN CHAD J | Chief Financial Officer | Stock Award(Grant) | Dec 7, 2023 | 42,578 |
| LEA DARRELL SHANE | Officer | Stock Award(Grant) | Dec 7, 2023 | 39,599 |
| LONGCOR JARROD | Chief Operating Officer | Stock Award(Grant) | Dec 7, 2023 | 53,141 |
| SHUSTOV ANDREI | Officer | Stock Award(Grant) | Dec 7, 2023 | 55,037 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 8.90% | 3,671,550 | 1.01M | Sep 29, 2024 |
| AIGH Capital Management LLC | 7.75% | 3,197,394 | 881.52K | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 6.57% | 2,712,443 | 747.82K | Sep 29, 2024 |
| Vanguard Group Inc | 4.18% | 1,726,986 | 476.13K | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 2.48% | 1,022,161 | 281.81K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.85% | 352,452 | 97.17K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.60% | 1,072,704 | 295.74K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.38% | 568,753 | 156.81K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.44% | 179,877 | 49.59K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.20% | 81,910 | 22.58K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 61,939 | 17.08K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 42,426 | 11.70K | Oct 30, 2024 |